(Q34443617)

2 August 2017

1 reference

title

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication (English)

1 reference

eradication of infectious diseases

2 August 2017

main subject

1 reference

poliovirus

1 reference

5

Mark A Pallansch

1 reference

2 August 2017

7

Roland W Sutter

1 reference

2 August 2017

4

M Steven Oberste

1 reference

2 August 2017

2

Marc S Collett

1 reference

2 August 2017

Mark A McKinlay

1

1 reference

2 August 2017

Jeffrey R Hincks

3

1 reference

2 August 2017

Hiromasa Okayasu

6

1 reference

2 August 2017

John F Modlin

8

1 reference

2 August 2017

Walter R Dowdle

9

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2014

1 reference

Journal of Infectious Diseases

2 August 2017

published in

1 reference

2 August 2017

volume

210 Suppl 1

1 reference

2 August 2017

page(s)

S447-53

1 reference

A case for developing antiviral drugs against polio

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION *

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Changes in population dynamics during long term evolution of Sabin type 1 poliovirus in an immunodeficient patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Inhibition of uncoating of poliovirus by arildone, a new antiviral drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Oral efficacy of WIN 51711 in mice infected with human poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Software extensions to UCSF chimera for interactive visualization of large molecular assemblies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

In vitro antiviral activity of V-073 against polioviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Treatment of potentially life-threatening enterovirus infections with pleconaril

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Immunogenicity of inactivated polio vaccine with concurrent antiviral V-073 administration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIU043

21 January 2018

Identifiers

DOI

10.1093/INFDIS/JIU043

1 reference

2 August 2017

1 reference